全文获取类型
收费全文 | 27372篇 |
免费 | 1315篇 |
国内免费 | 130篇 |
专业分类
耳鼻咽喉 | 398篇 |
儿科学 | 424篇 |
妇产科学 | 599篇 |
基础医学 | 3468篇 |
口腔科学 | 780篇 |
临床医学 | 1974篇 |
内科学 | 7350篇 |
皮肤病学 | 329篇 |
神经病学 | 2045篇 |
特种医学 | 790篇 |
外科学 | 4536篇 |
综合类 | 135篇 |
一般理论 | 1篇 |
预防医学 | 782篇 |
眼科学 | 405篇 |
药学 | 1849篇 |
中国医学 | 57篇 |
肿瘤学 | 2895篇 |
出版年
2023年 | 128篇 |
2022年 | 278篇 |
2021年 | 469篇 |
2020年 | 274篇 |
2019年 | 320篇 |
2018年 | 465篇 |
2017年 | 356篇 |
2016年 | 440篇 |
2015年 | 430篇 |
2014年 | 619篇 |
2013年 | 786篇 |
2012年 | 1202篇 |
2011年 | 1319篇 |
2010年 | 750篇 |
2009年 | 667篇 |
2008年 | 1286篇 |
2007年 | 1363篇 |
2006年 | 1289篇 |
2005年 | 1272篇 |
2004年 | 1236篇 |
2003年 | 1212篇 |
2002年 | 1225篇 |
2001年 | 936篇 |
2000年 | 970篇 |
1999年 | 847篇 |
1998年 | 361篇 |
1997年 | 269篇 |
1996年 | 262篇 |
1995年 | 223篇 |
1994年 | 209篇 |
1993年 | 179篇 |
1992年 | 634篇 |
1991年 | 658篇 |
1990年 | 562篇 |
1989年 | 563篇 |
1988年 | 542篇 |
1987年 | 512篇 |
1986年 | 438篇 |
1985年 | 439篇 |
1984年 | 327篇 |
1983年 | 248篇 |
1979年 | 235篇 |
1978年 | 140篇 |
1977年 | 144篇 |
1974年 | 128篇 |
1973年 | 122篇 |
1972年 | 137篇 |
1971年 | 128篇 |
1969年 | 140篇 |
1967年 | 132篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
Kazunori Aizawa Takeshi Hanaoka Hiroki Kasai Kaoru Kogashi Setsuo Kumazaki Jun Koyama Hiroshi Tsutsui Yoshikazu Yazaki Noboru Watanabe Osamu Kinoshita Uichi Ikeda 《Hypertension research》2006,29(2):123-128
The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more potent and selective PDE-5 inhibitor than sildenafil, has been approved for the treatment of erectile dysfunction. However, the long-term effects of oral vardenafil in patients with PH are unknown. We studied five consecutive patients with PH; one with primary pulmonary hypertension, two with chronic pulmonary thromboembolism, one with Eisenmenger syndrome (ventricular septal defect) and one with secondary pulmonary hypertension after a ventricular septal defect closure operation. In an acute hemodynamic trial, vardenafil (5 mg) significantly decreased both the pulmonary vascular resistance (PVR) and systemic vascular resistance (SVR) with an increase in cardiac output. In a chronic hemodynamic trial, the maintenance dose of vardenafil (10 to 15 mg) for 3 months significantly decreased the PVR, but not the SVR, with a 20.7% reduction of the PVR/ SVR ratio. Plasma brain natriuretic peptide (BNP) levels were also significantly decreased after 3 months. This pilot study demonstrates that long-term oral vardenafil therapy may be a safe and effective treatment for patients with PH. 相似文献
7.
Koji Saito Takashi Saito Sumio Kawada 《Nihon Shokakibyo Gakkai zasshi》2006,103(10):1176, 1179-1176, 1180
8.
Masahiro Yamauchi Hiroko Kusano Etsuko Saito Takeshi Iwata Masashi Nakakura Yasuki Kato Takaaki Uochi Shiro Akinaga Noboru Aoki 《Journal of controlled release》2006,114(2):268-275
Previously, we demonstrated that wrapping dextran fluorescein anionic/cationic lipid complexes with neutral lipids produced a stable formulation that markedly increased the duration of the compound in plasma after intravenous administration to rats. The improved drug-delivery properties of the wrapped liposomes (WL) relative to other formulations suggested that this technology could offer important advantages for the administration of other polyanionic drugs, including antisense oligodeoxynucleotides (ODN). In the present study, we investigated the value of WL for formulating fluorescence-labeled phosphorothioated ODN (F-ODN). WL encapsulating F-ODN/cationic lipid complexes were prepared efficiently using similar methodology to that used in our earlier study. Studies confirmed that these WL were stable in vitro. Following intravenous administration to mice, free F-ODN and naked F-ODN/cationic lipid complexes were rapidly eliminated whereas administration of the WL resulted in high blood concentrations of drug that were maintained for several hours. Additional studies were conducted in mice that were inoculated with tumor cells (Caki-1 xenograft model, human kidney); in these experiments, intravenous administration of WL delivered 13 times more F-ODN to the tumor site than achieved after injection of free F-ODN. 相似文献
9.